Plasma N-glycome composition associates with chronic low back pain. BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS. https://doi.org/10.1016/j.bbagen.2018.07.003
Plasma N-glycome composition associates with chronic low back pain


PII: S0304-4165(18)30186-7
DOI: doi:10.1016/j.bbagen.2018.07.003
Reference: BBAGEN 29152

To appear in: BBA - General Subjects

Received date: 20 March 2018
Revised date: 3 July 2018
Accepted date: 4 July 2018


This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Plasma N-Glycome Composition Associates With Chronic Low Back Pain


aGenos Glycoscience Research Laboratory, Zagreb, Croatia (iakmacic@genos.hr, fvuckovic@genos.hr, mvilaj@genos.hr, askelin@genos.hr, jkristic@genos.hr, jjuric@genos.hr, jsimunovic@genos.hr, jstambuk@genos.hr, mnovokmet@genos.hr)
bPolyOmica, Het Vlaggeschip 61, 5237 PA’s-Hertogenbosch, The Netherlands (l.c.karssen@polyomica.com, y.s.aulchenko@polyomica.com)
cThe Glycomics and Glycoproteomics group, Center for Proteomics and Metabolomics, Leiden University Medical Center, The Netherlands (a.momcilovic@lumc.nl)
dDepartment of Twin Research and Genetic Epidemiology, King’s College London, London, UK (massimo.mangino@kcl.ac.uk, frances.williams@kcl.ac.uk)
eNIHR Biomedical Research Centre at Guy’s and St Thomas’ Foundation Trust, London SE1 9RT, UK
fPain Therapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy (manuela.degregori@unipv.it)
gSIMPAR Group, Italy (mmarchesini@parmanesthesia.com, cdagostino@parmanesthesia.com, massimo.allegri@unipr.it)
hAnesthesia, Intensive Care and Pain Service, Parma Hospital, Parma, Italy
iDepartment of Medicine and Surgery, University of Parma, Parma, Italy
jCarolininas Pain Institute, Winston Salem, North Carolina, USA (rrauck@ccrpain.com, lkapural@ccrpain.com)
St. Catherine Specialty Hospital, Zabok/Zagreb, Croatia (draganprimorac2@gmail.com)

J J Strossmayer University of Osijek, School of medicine, Osijek, Croatia

University of Split, School of Medicine, Split, Croatia

Eberly College of Science, The Pennsylvania State University, University Park

Children’s Hospital Srebrnjak, Zagreb, Croatia

Department of anesthesiology and multidisciplinary pain center, Ziekenhuis Oost-Limburg, Genk, Belgium (k.buysse@zol.be, d.mesotten@zol.be, jan.vanzundert@zol.be)

Anesthesia and intensive care service - IRCCS MultiMedica Hospital, Sesto San Giovanni, Milano, Italy

University of Zagreb, Faculty of Pharmacy and Biochemistry, Zagreb, Croatia (glauc@pharma.hr)

* To whom correspondence should be addressed:

Prof. Gordan Lauc

University of Zagreb

Faculty of Pharmacy and Biochemistry

A. Kovačića 1

10 000 Zagreb, Croatia

Phone: +385 1 639 4467

Fax: +385 1 639 4400

E-mail: glauc@pharma.hr
Abstract

BACKGROUND: Low back pain (LBP) is the symptom of a group of syndromes with heterogeneous underlying mechanisms and molecular pathologies, making treatment selection and patient prognosis very challenging. Moreover, symptoms and prognosis of LBP are influenced by age, gender, occupation, habits, and psychological factors. LBP may be characterized by an underlying inflammatory process. Previous studies indicated a connection between inflammatory response and total plasma N-glycosylation. We wanted to identify potential changes in total plasma N-glycosylation pattern connected with chronic low back pain (CLBP), which could give an insight into the pathogenic mechanisms of the disease.

METHODS: Plasma samples of 1128 CLBP patients and 760 healthy controls were collected in clinical centers in Italy, Belgium and Croatia and used for N-glycosylation profiling by hydrophilic interaction ultra-performance liquid chromatography (HILIC-UPLC) after N-glycans release, fluorescent labeling and clean-up. Observed N-glycosylation profiles have been compared with a cohort of 126 patients with acute inflammation that underwent abdominal surgery.

RESULTS: We have found a statistically significant increase in the relative amount of high-branched (triantennary and tetra-antennary) N-glycan structures on CLBP patients’ plasma glycoproteins compared to healthy controls. Furthermore, relative amounts of disialylated and trisialylated glycan structures were increased, while high-mannose and glycans containing bisecting N-acetylglucosamine decreased in CLBP.

CONCLUSIONS: Observed changes in CLBP on the plasma N-glycome level are consistent with N-glycosylation changes usually seen in chronic inflammation.

GENERAL SIGNIFICANCE: To our knowledge, this is a first large clinical study on CLBP patients and plasma N-glycome providing a new glycomics perspective on potential disease pathology.

Keywords: glycan biomarker; low back pain; plasma N-glycosylation; retrospective study
Abbreviations

% Area: percentage of total integrated area of the chromatogram; 2-AB: 2-aminobenzamide; 2-PB: -picoline borane; AbSur: cohort of patients with acute inflammation that had abdominal surgery; ACE: automatic chromatogram extraction; ADCC: antibody-dependent cell-mediated cytotoxicity; ANCOVA: analysis of covariance; B - N-glycans that contain bisecting N-acetylglucosamine, BEL: samples from clinical centers in Belgium; CLBP: chronic low back pain; CRO: samples from clinical centers in Croatia; DMSO: dimethyl sulfoxide; FA: formic acid; FDR: false discovery rate; G0: agalactosylated N-glycans; G1: monogalactosylated N-glycans; G2: digalactosylated N-glycans; G3: trigalactosylated N-glycans; G4: tetragalactosylated N-glycans; GlcNAc: N-acetylglucosamine; GPs: glycan peaks; GU: glucose unit; HB - highly branched N-glycans; HILIC-SPE: hydrophilic interaction liquid chromatography solid phase extraction; HILIC-UPLC: hydrophilic interaction ultra-performance liquid chromatography; HM - high-mannose N-glycans; IgG: immunoglobulin G; ITA: samples from clinical centers in Italy; LB: low branched N-glycans; LBP: low back pain; LDD: lumbar disc degeneration; META: meta-analysis; MS: mass spectrometry; PBS: phosphate buffered saline; S0: neutral/not sialylated N-glycans; S1: monosialylated N-glycans; S2: disialylated N-glycans; S3: trisialylated N-glycans; S4: tetrasialylated N-glycans; SDS: sodium dodecyl sulfate; UPLC: ultra-performance liquid chromatography
1. Introduction

Low back pain (LBP) includes several mixed pain syndromes being one of the most common health problems in the world. Almost every adult has or will experience an episode of LBP and it is the number one cause of years lived with disability [1]. Prevalence of several frequently overlapping sources of LBP include sacroilitis 25-32 % [2,3], lumbal spondylosis 36-42 % [4–6], spinal stenosis, or lumbar radiculitis/radiculopathy up to 30 % [7,8]. When muscle tension, stiffness or pain are localized above the inferior gluteal folds and below the coastal margin, with or without leg pain, and last for three months or more, the condition is classified as chronic low back pain (CLBP). This is a group of syndromes with heterogeneous variable underlying mechanisms and molecular pathologies that correlate poorly with spine imaging. Additionally, symptoms and prognosis are influenced by many factors (gender [9], age [10], occupation, habits [11]), as well as physiological [12] and psychological factors [13,14], making managing the condition very challenging. The success of interventional techniques, such as epidural steroid injection, facet joints denervation, spinal cord stimulation or laminectomy, depends largely on the specific physiopathology of each patient. However, currently there is little evidence based approach to this disease, as biomarkers and prognostic factors practically do not exist.

In complex organisms, glycans (sugar moieties covalently attached to proteins) play an important role in virtually all processes that involve more than one cell [15]. Nearly all membrane and secreted proteins are modified by glycans with variable site occupancy and glycan composition [16,17]. Absence of N-glycosylation is embryonically lethal [18] and mutations that obstruct proper glycosylation cause debilitating diseases [19]. Inter-individual differences in N-glycosylation are associated with predisposition for and course of different diseases [20]. This is not surprising since the glycan parts of (glyco)proteins are integral elements of the final molecular structure, and together with amino acids in the polypeptide backbone, form a single molecular entity that performs biological functions. For example, glycans attached to immunoglobulin G (IgG) have very profound effects on protein structure and can convert IgG from a pro-inflammatory to an anti-inflammatory mode [21]. Alternative glycosylation (attachment of different glycans) affects binding of IgG to all Fc receptors and is in this way analogous to variation in protein sequence due to genetic variations [22].
Systemic and/or local inflammatory processes are believed to be an underlying mechanism in at least a subgroup of LBP patients, although this is not generally recognized. Previous studies indicated that inflammatory response associates with changes in total plasma N-glycosylation [23], as well as N-glycosylation of individual serum glycoproteins [24]. Since glycans affect not only protein structure, but also its function, a number of studies have shown that changes in glycosylation are implicated in the pathology of different diseases [25–28].

Glycosylation of individual glycoprotein, IgG, has already been studied in the context of LBP in a large study of 4511 twins from the TwinsUK database [29]. IgG glycans with core fucose (have lower antibody-dependent cell-mediated cytotoxicity, ADCC) and IgG glycans without core fucose (have higher ADCC activity) have been found to correlate with LBP, suggesting the involvement of ADCC and inflammation in LBP pathogenesis. However, there was no correlation found between lumbar disc degeneration (LDD) scores and IgG glycans, implicating different pathogenic mechanisms for specific LBP subtypes and supporting the role of glycans in inflammation-related LBP subtypes.

Considering previous research on inflammatory response association with changes in total plasma N-glycosylation [23], here, we studied the total plasma N-glycome in CLBP patients and controls in order to identify if there is an association between the N-glycosylation pattern on the level of total plasma glycoproteins and risk of CLBP condition. Specific pattern of plasma N-glycosylation could be used as a biomarker of CLBP, and potential indicator of both pathogenic mechanisms and therapy efficiency in future prospective and longitudinal studies.
2. Methods

2.1. Study approval

The study was approved by the ethical committees of the participating clinical centres between December 2013 and March 2014 and written informed consent was obtained from each participant prior to inclusion in the study. Participant samples have been de-identified by code. The study has been registered on clinicaltrials.gov (NCT02037789).

2.2. Clinical samples and data

Retrospective plasma samples of CLBP patients and healthy controls (people without acute or CLBP) were collected in several clinical centers in Italy, Belgium and Croatia that are involved in PainOmics project, following previously established and validated protocol for blood sample collection, storage and shipping [30,31] (Table 1). In short, blood for glycomics analysis has been collected into EDTA containing vacutainer tube and mixed well for balanced clotting. Tube was left at room temperature for 1 hour and plasma was separated by centrifugation at 1620 g for 10 minutes, transferred to a clean tube and centrifuged again at 2700 g for 10 minutes. Volume of 1 mL of plasma after second centrifugation step has been transferred to a clean tube and stored at -80 °C or -20 °C before further processing. CLBP patients were defined according to previously published criteria [31]: all Caucasian adult patients, referred to participant pain clinics, with pain localized to the column between the costal margins and gluteal fold, with or without symptoms into one or both legs, that was lasting more than 12 weeks. We excluded all patients with an acute episode of LBP, any history of spine tumor or infection or recent (less than 12 months) vertebral fractures, or psychiatric disorders. All patients have been classified into 6 major groups: spinal stenosis, discogenic pain, facet joint pain, sacroiliac joint pain, low back pain associated to radicular pain (radicular pain not predominant) and wide-spread LBP. Furthermore, all patients’ pain characteristics (intensity and type of pain) have been evaluated with painDETECT [32].

Plasma samples from cohort of patients with acute inflammation that underwent abdominal surgery (AbSur) were collected in several clinical centers in Italy as described earlier [33,34]. Blood samples of 126 patients have been taken in several time points - intraoperatively and 6, 12, 24, and 48 hours after the
surgery. Samples taken intraoperatively and 48 hours after abdominal surgery have been considered as “Case” or “Control”, respectively. In short, blood for glycomics analysis has been collected into EDTA containing vacutainer tube, mixed well for balanced clotting and plasma was separated by centrifugation at room temperature. Samples have been stored at -20 °C before further processing.

2.3. *Deglycosylation of plasma samples*

All plasma samples and in-house plasma standards were vortexed after thawing and centrifuged for 3 minutes at 12 100 g. Each sample (10 μL) was aliquoted to 1 mL 96-well collection plates (Waters, Milford, MA, USA) following a predetermined experimental design, which was blocked on case-control status, sex and age information (each 96-well plate represents the whole population in terms of case-control status, sex and age distribution), while the rest was randomized. In-house plasma standards were aliquoted in four to five replicates per plate, to control for batch effects, that is plate-to-plate variation.

Plasma proteins were denatured by adding 20 μL of 2 % (w/v) sodium dodecyl sulfate (SDS, Invitrogen, Carlsbad, CA, USA) and sample incubation at 65 °C for 10 minutes. After cooling to room temperature for 30 minutes, 10 μL of 4 % (v/v) Igepal CA-630 (Sigma-Aldrich, St. Louis, MO, USA) was added to each sample and the mixture was shaken for 15 minutes at room temperature on a plate shaker. Plasma proteins were deglycosylated by incubation at 37 °C for 18 hours after 1.2 U of PNGase F (10 U μL⁻¹, Promega, Madison, WI, USA) in 10 μL of 5× PBS was added to each sample. Buffer 5× PBS was made in house: 685 mmol L⁻¹ NaCl (Carlo Erba, Peypin, Italy), 13.5 mmol L⁻¹ Na₂HPO₄ (Acros Organics, Thermo Fisher Scientific, Geel, Belgium), 48.5 mmol L⁻¹ KH₂PO₄ (Sigma-Aldrich), 11 mmol L⁻¹ KCl (Gram-Mol, Zagreb, Croatia), and filtered through 0.2 μm Supor PES filters (Nalgene Thermo Fischer Scientific).

2.4. *Fluorescent labeling and clean-up of released plasma N-glycans*

Released plasma N-glycans were subsequently labeled with a fluorescent dye 2-aminobenzamide (2-AB, Sigma-Aldrich). The labeling mixture was freshly prepared by dissolving 0.48 mg of 2-AB and 1.12 mg of 2-picoline borane (2-PB, Sigma-Aldrich) in 25 μL of dimethyl sulfoxide (DMSO, Sigma-Aldrich) and glacial acetic acid (Merck, Darmstadt, Germany) (7:3, v/v), per sample. Labeling mixture was added to each
sample and the plate was sealed with an adhesive seal. Samples were mixed for 10 minutes at room temperature, and incubated at 65 °C for 2 hours for the labeling reaction to take place.

Released and fluorescently labeled plasma N-glycans were cleaned of excess of reagents and proteins by previously developed and optimized hydrophilic interaction liquid chromatography solid phase extraction (HILIC-SPE) procedure [35]. After labelling, reaction samples were cooled down to room temperature for 30 minutes and 700 µL of cold (4 °C) acetonitrile (Sigma-Aldrich) was added to each sample and gently mixed. The clean-up procedure was performed on a hydrophilic 0.2 µm AeroPrep GHP filter plate (Pall Corporation, Ann Arbor, MI, USA) using a vacuum manifold (Pall Corporation) at around 25 mm Hg. All wells of a GHP filter plate were prewashed with 200 µL of 70 % ethanol in water, 200 µL of ultra-pure water and 200 µL of 96 % cold (4 °C) acetonitrile in water. The samples diluted with cold acetonitrile were loaded to the wells, incubated on a filter for 2 minutes and subsequently washed with 5× 200 µL of 96 % cold (4 °C) acetonitrile in water. Glycans were eluted from a filter plate with 2× 90 µL of ultra-pure water after 15 minutes of shaking at room temperature and centrifugation at 164 g in each step. Combined eluates were stored at -20 °C until the UPLC analysis.

2.5. Plasma N-glycan analysis by HILIC-UPLC

Fluorescently labelled and purified plasma N-glycans were prepared in 75 % acetonitrile (v/v) and analyzed by HILIC-UPLC on an Acquity UPLC instrument (Waters) consisting of a quaternary solvent manager, sample manager and a fluorescence detector. The 2-AB labeled N-glycans were separated on a Waters BEH Glycan chromatography column, 150 × 2.1 mm i.d., 1.7 µm BEH particles, in a linear gradient of 30–47 % 100 mmol L⁻¹ ammonium formate, pH 4.4 (solvent A) and acetonitrile (solvent B) at flow rate of 0.56 mL min⁻¹ and a 23 minutes analytical run. Samples were maintained at 10 °C before injection into the column, the column temperature was 25 °C and separated glycans were detected at excitation wavelengths of 250 nm and emission wavelength of 428 nm. The UPLC system was under the control of the Empower 3 software, build 3471 (Waters). Chromatograms were processed using an automatic processing method and manually corrected to maintain the same intervals of integration across all samples, or processed with a recently developed semi-supervised Automatic Chromatogram Extraction (ACE) method [36] for automated
alignment and detection of glycan peaks in chromatograms. The plasma N-glycan samples were all separated into 39 glycan peaks (GPs) and the amount of glycans in each chromatographic peak was expressed as percentage of total integrated area (% Area). To each detected chromatographic peak a glucose unit (GU) value was assigned according to external standard of hydrolysed and 2-AB labelled glucose oligomers (dextran ladder) which was run with every analytical UPLC batch [37].

2.5.1 Confirmation of the HILIC-UPLC plasma glycome profile

The major glycan present in each of the reported 39 chromatographic peaks was annotated according to GU values, measured m/z value, recorded fragmentation spectra where applicable and according to previously published and annotated serum N-glycome profile [38] (Supplementary Table 1). Several representative samples from control and patient groups were selected and analysed by HILIC-UPLC, as described in previous section, additionally hyphenated to the Bruker compact Q-Tof mass spectrometer (MS), both controlled using HyStar software (Bruker, Bremen, Germany) version 4.1. UPLC was coupled to MS via Ion Booster (Bruker) ion source with aditional flow of 100 μL min⁻¹ of acetonitrile introduced into analytical flow using a t-piece. Capillary voltage was set to 2250 V with nebulizing gas at pressure of 5.5 Bar. Drying gas was applied to source at a flow rate of 4 L min⁻¹ and temperature of 100 °C, while vaporiser temperature was set to 220 °C and flow rate of 5 L min⁻¹. Nitrogen was used as a source gas, while argon was used as collision gas. Ion energy was set to 5 eV, transfer time was 100 μs. Spectra were recorded in mass range from 50 m/z to 4000 m/z at a rate of 0.5 Hz. For MS acquisition collision energy was set to 4 eV and Rf 4200 Vpp. Fragment spectra were acquired using auto MS/MS mode using a precursor ion list of detected m/z values corresponding to free 2-AB labelled plasma glycans (Supplementary Table 1). Active exclusion was set to one minute after three spectra and number of precursor ions was 1. All recorded spectra were analysed using Bruker Data Analysis software version 4.4 (Bruker). Glycan compositions and certain structural features were determined using GlycoMod [39] and GlycoWorkbench [40].

2.6. Statistics
In order to remove experimental variation from the measurements, normalization and batch correction were performed on the UPLC glycan data. To make measurements across samples comparable, normalization by total area was performed where the peak area of each of the 39 glycan containing peaks was divided by total area of the corresponding chromatogram. Prior to batch correction, normalized glycan measurements were log-transformed due to right-skewness of their distributions and the multiplicative nature of batch effects. Batch correction was performed on log-transformed measurements using the ComBat method (R package “sva3.6.0”) [41], where the technical source of variation (which sample was analyzed on which plate) was modeled as batch covariate. To correct the measurements for experimental noise, estimated batch effects were subtracted from log-transformed measurements. In addition to the 39 directly measured glycan containing peaks, 14 derived traits were calculated from the directly measured glycans (Table 2). These derived traits average particular glycosylation features across different individual glycan structures and consequently they are more closely related to individual enzymatic activities and underlying genetic polymorphisms.

Association analyses between disease status and glycan traits were performed using an analysis of covariance (ANCOVA) model with age and gender included as covariates. Analyses were first performed for each cohort separately and then combined using inverse-variance weighted meta-analysis (META, R package “metaphor v1.9-4”) [42]. Prior to the analyses, the glycan variables were all transformed to the standard Normal distribution (mean = 0, sd = 1) by inverse transformation of ranks to Normality (R package “GenABEL v1.8-0”, function rntransform) [43]. Using rank transformed variables in analyses makes estimated effects of different glycans in different cohorts comparable as transformed glycan variables have the same standardized variance. In case-control regression analysis, coefficients of binary predictors refer to a change in a glycan variable between 2 classes of binary predictors expressed in SDs. The false discovery rate (FDR) was controlled using the Benjamini-Hochberg procedure, and p-values corrected for multiple testing (with FDR cutoff set at 0.05) are shown throughout.

Data was analyzed and visualized using R programming language (version 3.0.1).
3. Results

3.1. Glycosylation changes in three cohorts

Patients and healthy volunteers were enrolled in the study through clinical centers in Italy (ITA), Belgium (BEL) and Croatia (CRO). Total plasma N-glycosylation was analysed by ultra-performance liquid chromatography (UPLC) (Figure 1) in 1128 CLBP patients and 760 healthy controls (Table 1). This type of analysis represents the first step in a biomarker discovery – a snapshot of the differences in N-glycosylation pattern between CLBP patients and controls.

We observed statistically significant differences in relative abundance of several major structurally similar glycan groups represented as derived glycosylation traits (Figure 2, Table 2 and 3) between CLBP patients and healthy controls of the ITA and BEL cohorts. A similar trend was also seen in the CRO cohort, although not significant after correction for multiple comparisons (Figure 2, Table 3). All glycan groups (derived glycosylation traits) that were shown to be significantly changed change in the same direction (column “effect” in Table 3) regardless of the clinical center of study participants’ enrolment, demonstrating consistent changes of total plasma N-glycosylation in patients with CLBP compared to controls.

On the other hand, some differences in relative abundance of several derived glycosylation traits can be seen between controls enrolled in different clinical centers and the same is observed for patients (Figure 2). Since extreme care has been taken to standardize all steps of the study [30] – from blood sample collection to sample processing, storage and shipping, these changes can probably be attributed to differences in populations (e.g. different genetic and environment background), which are known to affect plasma glycome composition [44].

3.2. Changes in derived N-glycan structural features between CLBP and controls

The relative area of chromatographic peaks corresponding to highly branched – denoted as “HB” in Table 3 – glycan structures is increased (and, concomitantly, the % Area of chromatographic peaks corresponding to glycan structures with low branching – denoted as “LB” in Table 3 – is decreased) in CLBP patients compared to controls, which is consistent with previous findings of increased branching in chronic inflammation [45–47].
Interestingly, while the % Area of chromatographic peaks corresponding to monosialylated (S1) and tetraysialylated (S4) glycan structures were similar or lower in CLBP patients compared to controls, the percentage areas of disialylated (S2) and trisialylated (S3) glycan structures were increased in CLBP patients compared to controls (Table 3, Figure 2).

Unsurprisingly, changes in galactosylation levels were similar to sialylation, reflecting the fact that galactose is a prerequisite for glycan sialylation. A different trend can only be observed in monogalactosylated (G1) structures, which are lower in CLBP patients compared to controls, while monosialylated (S1) structures are similar or slightly lower in patients compared to controls.

High-mannose glycans (HM) and glycans that contain bisecting N-acetylglucosamine (B) have shown the same pattern of change between CLBP patients and controls (Figure 2). This decrease in % Areas of chromatographic peaks corresponding to HM and B glycan structures in CLBP patients compared to controls was statistically significant in ITA and CRO cohorts, but did not reach the statistical significance in BEL cohort (Table 3).

### 3.3. Glycosylation in CLBP and inflammation

Since similar changes in the glycome were observed in a previously analyzed AbSur cohort, we have compared total plasma N-glycosylation changes from AbSur study with the total plasma N-glycosylation changes in CLBP study (Figure 2). For the majority of derived glycosylation traits the changes in the CLBP patients were in the same direction as in patients with acute inflammation compared to controls, but the extent of the change was somewhat smaller in CLBP. This finding indicates that CLBP is associated with systemic inflammation in at least a subgroup of patients. However, due to the cross-sectional nature of this study (plasma samples collected after CLBP development), we could not investigate longitudinal changes of plasma N-glycome through CLBP condition development and progression, and whether a changed N-glycomic profile during inflammation is a pre-requisite for CLBP condition development, or merely a consequence of CLBP progression.
4. Discussion

Phenotypic diversity caused by differences in glycosylation has not been investigated to a large extent. We pioneered high-throughput glycomics screening of human populations in 2009 [48] and since then analysed over 50,000 individual glycomes through numerous clinical and epidemiological studies. Our large-scale glycomics studies revealed very high inter-individual variability of both, the plasma N-glycome [44] and the IgG glycome [49]. However, within an individual, the composition of the N-glycome was found to have significant short-term (in the order of weeks) stability in homeostatic conditions [50].

In a previous study [29] we found, in a large cohort of twins, a correlation between LBP and IgG glycan modules featuring glycans that either promote or block ADCC. On the other hand, we have not found any correlation between LDD and glycan structures suggesting that inflammation is not connected with this specific subtype of LBP. Although in this study we explored one aspect of LBP, complex pathophysiology of this condition still remains poorly understood and biomarker potential of N-glycome not yet defined. Additionally, a genome wide association study of LBP in over 400,000 individuals revealed only three replicable associations between genetic variants (not related explicitly to glycosylation) and LBP, indicating that genetics has very limited potential for stratification of LBP patients (manuscript in submission).

Therefore, the disease mechanisms underlying the syndrome of CLBP remain incompletely understood, making patient prognosis and therapy challenging. Previous studies implicated protein glycosylation as one of the players involved in inflammation [29]. To deepen our understanding of CLBP pathology and potentially improve therapy efficiency on an individual patient basis, we explored changes in total plasma N-glycosylation in 1888 healthy individuals and CLBP patients in an international multi-center retrospective clinical study.

We found statistically significant differences in plasma N-glycosylation between patients and matching (by age, gender and clinical centre) healthy controls consistent with changes in glycosylation previously reported for chronic inflammation – an increase in the level of high-branched glycan structures [45–47]. Increase in N-glycan branching is a result of N-acetylglucosaminyl (GlcNAc) transferase IV (transfers β1,4-linked GlcNAc to tri-manosyl core creating a third antenna) and GlcNAc transferase V (transfers β1,6-linked GlcNAc to the tri-mannosyl core creating a fourth antenna) function [51]. One of the
plasma glycoproteins that contributes to majority of tri-antennary and tetra-antennary sialylated (highly branched) glycans is α-1-acid glycoprotein [52], which is an acute phase protein whose concentration significantly increases as a response to inflammatory stimuli. Interestingly, it has been shown that the relative abundance of total bi-antennary glycans and α1,3-fucosylated bi-, tri- and tetra-antennary α-1-acid glycoprotein glycan structures are increasing in acute and chronic inflammation compared to healthy individuals, while the relative abundance of total tri-antennary and total tetra-antennary glycans are decreasing [53]. Fucose bound in an α1,3 linkage to the antenna is part of a sialyl Lewis X (SLex) structure that consists of a terminal α2,3-sialic acid residue linked to galactose that is attached to GlcNAc. Increase in SLex structures is another previously identified signature of chronic inflammation [54].

Increased levels of glycans with bisecting GlcNAc has been previously connected with inflammation, mostly on the level of IgG [55]. On the other hand, it is known that presence of bisecting GlcNAc during glycan synthesis prevents formation of tri-antennary and tetra-antennary glycan structures, causing a decrease in glycan branching [51]. Since the relative amount of high- branched glycan structures on the level of total plasma glycoproteins was increased in CLBP patients compared to controls, it is not surprising that glycans containing bisecting GlcNAc were decreased in CLBP.

Although high-mannose glycans are usually not very abundant in secreted proteins relative to other glycan types and are considered to be incomplete products of the N-glycosylation process, its importance via interactions with mannose receptors on macrophages and dendritic cells as part of the innate immune response is well recognized [56]. Additionally it has been shown that high-mannose glycans increase serum clearance of IgG [57] and can initiate complement pathway by binding to mannose-binding lectin [58].

Observed increase in disialylated and trisialylated glycan structures in CLBP patients potentially indicate an increase in relative abundance of these specific glycan structures or an amount of specific glycoproteins carrying disialylated and trisialylated glycans, instead of a systematic increase in level of total plasma glycoproteins sialylation. These targeted changes in disialylated and trisialylated glycan structures in CLBP are a novel finding.

To the best of our knowledge, this is a first large clinical study on CLBP patients and healthy individuals providing a total plasma N-glycomics perspective and a potential biomarker for this phenotype.
The next step would be population stratification according to their inflammatory response. We are currently evaluating patients with acute LBP observing if they develop or do not develop chronic pain. With this prospective study we plan to go a step further and evaluate a biomarker potential of glycome in acute systemic inflammation.
Author contributions

MM, RR, DP, LK, FMKW, JvZ, MA, and GL designed the research study. AS, MDG, MM, CD, KB and DM acquired samples and research study participants’ data. IT-A, MV, AS, JK, JJ, AM, JŠ, JŠ and MN performed the experiments. FV, LCK, and YSA performed quality control and analyzed the data. IT-A, FV, and GL drafted the manuscript and all authors edited the final version of the manuscript.

Acknowledgements

This research was supported by the European Commission FP7 “PainOmics” project (contract No. 602736), as well as funding from the European Structural and Investments funds for project ”Croatian National Centre of Research Excellence in Personalized Healthcare” (contract No. KK.01.1.1.01.0010). AM and JŠ are part of the “GlyCoCan” project, which is funded from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No. 676421.

We would like to thank all participants enrolled in this study through clinical centers in Italy (PainTherapy Service, Fondazione IRCCS Policlinico San Matteo, Pavia; and Anesthesia, Critical Care and Pain Medicine Unit, Division of Surgical Sciences, Department of Medicine and Surgery, University of Parma, Parma), Belgium (Department of anesthesiology and multidisciplinary pain center, Ziekenhuis Oost-Limburg, Genk, Belgium), and Croatia (St. Catherine Specialty Hospital, Zabok/Zagreb, Croatia).

Conflict of interest statement

G. Lauc is the founder and owner of Genos Ltd, a private research organization that specializes in high-throughput glycomic analysis and has several patents in this field. I. Trbojević-Akmačić, F. Vučković, M. Vilaj, A. Skelin, J. Krištić, J. Jurić, A. Momčilović, J. Šimunović, J. Štambuk, M. Novokmet are employees of Genos Ltd. Y. S. Aulchenko and L. C. Karssen are owners of Maatschap PolyOmica, a private organization providing services and doing research and development in the field of computational and statistical (gen)omics. All other authors declare no conflicts of interest.
FIGURE LEGENDS

Figure 1. **A) Representative plasma N-glycans chromatographic profile.** Glycans labeled with 2-aminobenzamide have been separated by ultra-performance liquid chromatography (UPLC) based on hydrophilic interactions (HILIC). Major glycan structures are shown for each glycan containing chromatographic peak (GP1–GP39). **B) Different plasma N-glycosylation profiles of a healthy individual (Control) and a chronic low back pain patient (Case).** Chromatographic profiles have been overlayed and scaled to the highest peak.

Figure 2. **Changes in total plasma N-glycosylation in chronic low back pain (CLBP).** Relative abundance (%Area, the percentage of total plasma N-glycan pool) of major plasma N-glycan groups (derived traits, cf. Table 2) between healthy individuals (Control) and chronic low back pain patients (Case) collected in three clinical centers in Italy (ITA), Belgium (BEL) and Croatia (CRO), as well as comparison with patients that underwent abdominal surgery (AbSur) has been shown. Data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the 10th and 90th percentiles. Circles indicate outliers.
References

McKee, A. McLain, B.J. McMahon, P.A. Meaney, M.M. Mehndiratta, F. Mejia-Rodriguez, W.
Mekonnen, Y.A. Melaku, M. Meltzer, Z.A. Memish, G. Mensah, A. Meretoja, F.A. Mhimbira, R.
Mohammad, A.H. Mokdad, G.L. Mola, L. Monasta, M. Montico, T.J. Montine, A.R. Moore, A.E.
Moran, L. Morawska, R. Mori, J. Moschandreas, W.N. Moturi, M. Moyer, D. Mozaffarian, U.O.
Neupane, L.M. Newman, C.R. Newton, M. Ng, F.N. Ngalesoni, N.T. Nhung, M.I. Nisar, S. Nolte,
O.F. Norheim, R.E. Norman, B. Norrving, L. Nyakarahuka, I.H. Oh, T. Ohkubo, S.B. Omer, J.N.
Opio, A. Ortiz, J.D. Pandian, C.I.A. Panelo, C. Papachristou, E.K. Park, C.D. Parry, A.J.P. Caicedo,
S.B. Patten, V.K. Paul, B.I. Pavlin, N. Pearce, L.S. Pedraza, C.A. Pellegrini, D.M. Pereira, F.P. Perez-
Poulton, F. Pourmalek, D. Prabhakaran, N.M. Prasad, D. Qato, D.A. Quistberg, A. Rafay, K. Rahimi,
V. Rahimi-Movaghar, S.U. Rahman, M. Raju, I. Rakovac, S.M. Rana, H. Razavi, A. Refaat, J. Rehm,
G. Remuzzi, S. Resnikoff, A.L. Ribeiro, P.M. Riccio, L. Richardson, J.H. Richardus, A.M. Riederer,
M. Robinson, A. Roca, A. Rodriguez, D. Rojas-Rueda, L. Ronfani, D. Rothenbacher, N. Roy, G.M.
Ruhago, N. Sabin, R.L. Sacco, K. Ksoreide, S. Saha, R. Sahatvean, M.A. Sahraian, U. Sampson, J.R.
Scarborough, B. Schoettker, I.J.C. Schneider, D.C. Schwebel, J.G. Scott, S. Seedat, S.G. Sepanlou, B.
Serdar, E.E. Servan-Mori, K. Shackelford, A. Shaheen, S. Shahrzad, T.S. Levy, S. Shangguan, J. She,
S. Sheikhbahaei, D.S. Shepard, P. Shi, K. Shibuya, Y. Shinhara, R. Shiri, K. Shishani, I. Shiue, M.G.
Shrime, I.D. Sigfusdottir, D.H. Silberberg, E.P. Simard, S. Sindi, J.A. Singh, L. Singh, V. Skirbekk,
Stoeckl, V.K. Stathopoulou, N. Steckling, M.B. Stein, D.J. Stein, T.J. Steiner, A. Stewart, E. Stork,


[34] I. Gudelj, M. Baciarello, I. Ugrina, M. De Gregori, V. Napolioni, P.M. Ingelmo, D. Bugada, S. De Gregori, L. Derek, M. Pučić-Baković, M. Novokmet, O. Gornik, G. Saccani Jotti, T. Meschi, G. Lauc,


R. Saldova, A. Asadi Shehni, V.D. Haakensen, I. Steinfeld, M. Hilliard, I. Kifer, Å. Helland, Z.


[54] E.C.M. Brinkman-Van Der Linden, P.F. De Haan, E.C. Havenaar, W. Van Dijk, Inflammation-induced expression of sialyl Lewis(x) is not restricted to α1-acid glycoprotein but also occurs to a lesser extent on α1-antichymotrypsin and haptoglobin, Glycoconj. J. 15 (1998) 177–182.


Table 1. Information about participants enrolled in a chronic low back pain study.

<table>
<thead>
<tr>
<th>Sample Number</th>
<th>ITA Case</th>
<th>ITA Control</th>
<th>BEL Case</th>
<th>BEL Control</th>
<th>CRO Case</th>
<th>CRO Control</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (med/IQR)</td>
<td>67 (51-76)</td>
<td>68 (50-77)</td>
<td>56 (49-67)</td>
<td>56 (48-65)</td>
<td>55 (48-65)</td>
<td>56 (41-65)</td>
</tr>
<tr>
<td>Sex (F) (n/%)</td>
<td>201 (53.6%)</td>
<td>205 (54.1%)</td>
<td>309 (54.5%)</td>
<td>108 (56.5%)</td>
<td>120 (64.5%)</td>
<td>79 (41.6%)</td>
</tr>
</tbody>
</table>

Plasma N-glycosylation analysis has been performed for participants from three clinical centers in Italy (ITA), Belgium (BEL) and Croatia (CRO). Case - chronic low back pain patients, Control - healthy individuals, med - median value, IQR - interquartile range.
Table 2. Derived glycan traits defined from 39 directly measured chromatographic peaks corresponding to glycans with similar structural features (Figure 1).

<table>
<thead>
<tr>
<th>Structural feature</th>
<th>Chromatographic peaks corresponding to glycans with designated feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>HB (High-branching)</td>
<td>GP24+GP25+GP26+GP27+GP28+GP29+GP30+GP31+GP32+GP33+GP34+GP35+GP36+GP37+GP38+GP39</td>
</tr>
<tr>
<td>S0 (Neutral/not sialylated glycans)</td>
<td>GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11</td>
</tr>
<tr>
<td>S1 (Monosialylated glycans)</td>
<td>GP12+GP13+GP14+GP15+GP16+GP17</td>
</tr>
<tr>
<td>S2 (Disialylated glycans)</td>
<td>GP18+GP20+GP21+GP22+GP23+GP24+GP25+GP26</td>
</tr>
<tr>
<td>S3 (Triisialylated glycans)</td>
<td>GP27+GP28+GP29+GP30+GP31+GP32+GP33+GP34+GP35</td>
</tr>
<tr>
<td>S4 (Tetrasialylated glycans)</td>
<td>GP36+GP37+GP38+GP39</td>
</tr>
<tr>
<td>G0 (Agalactosylated glycans)</td>
<td>GP1+GP2</td>
</tr>
<tr>
<td>G1 (Monogalactosylated glycans)</td>
<td>GP3+GP4+GP5+GP6+GP12+GP13</td>
</tr>
<tr>
<td>G2 (Digalactosylated glycans)</td>
<td>GP8+GP9+GP10+GP11+GP14+GP15+GP16+GP17+GP18+GP20+GP21+GP22+GP23</td>
</tr>
<tr>
<td>G3 (Trigalactosylated glycans)</td>
<td>GP24+GP25+GP26+GP27+GP28+GP29+GP30+GP31+GP32+GP35</td>
</tr>
<tr>
<td>G4 (Tetragalactosylated glycans)</td>
<td>GP33+GP34+GP36+GP37+GP38+GP39</td>
</tr>
<tr>
<td>HM (High-mannose glycans)</td>
<td>GP2+GP7+GP19</td>
</tr>
<tr>
<td>B (bisecting N-acetylglucosamine containing glycans)</td>
<td>GP2+GP3+GP6+GP9+GP11+GP12+GP15+GP17+GP21+GP23</td>
</tr>
</tbody>
</table>

GP - glycan peak. LB - monoantennary and biantennary glycans, HB - tri-antennary and tetra-antennary glycans, S0 - glycans with no sialic acid, S1 - glycans with one sialic acid, S2 - glycans with two sialic acids, S3 - glycans with three sialic acids, S4 - glycans with four sialic acids, G0 - glycans with no galactose, G1 - glycans with one galactose, G2 - glycans with two galactoses, G3 - glycans with three galactoses, G4 - glycans with four galactoses, HM - high-mannose glycans, B - glycans that contain bisecting N-acetylglucosamine.
Table 3. Differences in derived structural features (TRAITs, defined in Table 2) of plasma protein N-glycans (Figure 1) between chronic low back pain cases and healthy controls in the three populations - Italy (ITA), Belgium (BEL) and Croatia (CRO), together with meta-analysis of all three populations (META).

<table>
<thead>
<tr>
<th>TRAIT</th>
<th>ITA</th>
<th></th>
<th></th>
<th>BEL</th>
<th></th>
<th></th>
<th>CRO</th>
<th></th>
<th></th>
<th>META</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>eff ec</td>
<td>SE</td>
<td>p.val</td>
<td>eff ec</td>
<td>SE</td>
<td>p.val</td>
<td>eff ec</td>
<td>SE</td>
<td>p.val</td>
<td>eff ec</td>
<td>SE</td>
</tr>
<tr>
<td>LB (Low-branching)</td>
<td>0.0</td>
<td>0.4</td>
<td>2.23</td>
<td>3.47</td>
<td>0.3</td>
<td>2.81</td>
<td>0.394E-</td>
<td>0.1</td>
<td>3.39</td>
<td>5.05</td>
<td>0.1</td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>72</td>
<td>E-03</td>
<td>E-03</td>
<td>40</td>
<td>81</td>
<td>E-05</td>
<td>04</td>
<td>15</td>
<td>E-01</td>
<td>E-01</td>
</tr>
<tr>
<td>HB (High-branching)</td>
<td>0.0</td>
<td>0.2</td>
<td>2.18</td>
<td>3.47</td>
<td>0.2</td>
<td>0.0</td>
<td>4.76</td>
<td>1.11E-</td>
<td>0.0</td>
<td>0.1</td>
<td>4.48</td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>72</td>
<td>E-03</td>
<td>E-03</td>
<td>84</td>
<td>81</td>
<td>E-04</td>
<td>03</td>
<td>91</td>
<td>21</td>
<td>E-01</td>
</tr>
<tr>
<td>S0 (Neutral)</td>
<td>0.4</td>
<td>0.0</td>
<td>5.45</td>
<td>3.44</td>
<td>0.3</td>
<td>0.0</td>
<td>1.23</td>
<td>7.26E-</td>
<td>0.1</td>
<td>1.23</td>
<td>3.05</td>
</tr>
<tr>
<td></td>
<td>0.4</td>
<td>71</td>
<td>E-10</td>
<td>E-09</td>
<td>19</td>
<td>83</td>
<td>E-04</td>
<td>04</td>
<td>86</td>
<td>21</td>
<td>E-01</td>
</tr>
<tr>
<td>S1 (Monosialylated)</td>
<td>0.0</td>
<td>0.0</td>
<td>7.05</td>
<td>7.05</td>
<td>0.0</td>
<td>0.0</td>
<td>9.27</td>
<td>9.27E-</td>
<td>0.1</td>
<td>1.71</td>
<td>3.41</td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>72</td>
<td>E-01</td>
<td>E-01</td>
<td>08</td>
<td>83</td>
<td>E-01</td>
<td>01</td>
<td>63</td>
<td>20</td>
<td>E-01</td>
</tr>
<tr>
<td>S2 (Disialylated)</td>
<td>0.3</td>
<td>0.1</td>
<td>1.36</td>
<td>3.17</td>
<td>0.1</td>
<td>0.0</td>
<td>5.56</td>
<td>8.65E-</td>
<td>0.1</td>
<td>0.1</td>
<td>1.16</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>71</td>
<td>E-06</td>
<td>E-06</td>
<td>60</td>
<td>84</td>
<td>E-02</td>
<td>02</td>
<td>90</td>
<td>21</td>
<td>E-01</td>
</tr>
<tr>
<td>S3 (Trisialylated)</td>
<td>0.2</td>
<td>0.0</td>
<td>4.53</td>
<td>5.76</td>
<td>0.2</td>
<td>0.0</td>
<td>3.11</td>
<td>1.09E-</td>
<td>0.1</td>
<td>0.1</td>
<td>1.31</td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>73</td>
<td>E-03</td>
<td>E-03</td>
<td>97</td>
<td>82</td>
<td>E-04</td>
<td>03</td>
<td>82</td>
<td>21</td>
<td>E-01</td>
</tr>
<tr>
<td>S4 (Tetrasialylated)</td>
<td>0.1</td>
<td>0.0</td>
<td>1.07</td>
<td>1.25</td>
<td>0.0</td>
<td>0.0</td>
<td>5.59</td>
<td>7.12E-</td>
<td>0.0</td>
<td>0.1</td>
<td>4.31</td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>71</td>
<td>E-01</td>
<td>E-01</td>
<td>48</td>
<td>83</td>
<td>E-01</td>
<td>01</td>
<td>23</td>
<td>48</td>
<td>E-01</td>
</tr>
<tr>
<td>G0 (Agalactosylated)</td>
<td>0.3</td>
<td>0.0</td>
<td>1.85</td>
<td>2.59</td>
<td>0.2</td>
<td>0.0</td>
<td>4.03</td>
<td>1.11E-</td>
<td>0.1</td>
<td>0.1</td>
<td>3.11</td>
</tr>
<tr>
<td></td>
<td>0.3</td>
<td>62</td>
<td>E-10</td>
<td>E-09</td>
<td>77</td>
<td>84</td>
<td>E-03</td>
<td>03</td>
<td>13</td>
<td>14</td>
<td>E-01</td>
</tr>
<tr>
<td>G1 (Monogalactosylated)</td>
<td>0.4</td>
<td>0.0</td>
<td>3.18</td>
<td>1.11</td>
<td>0.3</td>
<td>0.0</td>
<td>1.56</td>
<td>7.26E-</td>
<td>0.1</td>
<td>0.1</td>
<td>3.60</td>
</tr>
<tr>
<td></td>
<td>0.4</td>
<td>71</td>
<td>E-09</td>
<td>E-08</td>
<td>11</td>
<td>82</td>
<td>E-04</td>
<td>04</td>
<td>19</td>
<td>11</td>
<td>E-01</td>
</tr>
<tr>
<td>Trait</td>
<td>Effect</td>
<td>Beta Coefficient</td>
<td>SE</td>
<td>p.val</td>
<td>q.val</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------------------</td>
<td>--------</td>
<td>------------------</td>
<td>-----</td>
<td>-------</td>
<td>-------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G2 (Digalactosylated)</td>
<td>0.2</td>
<td>0.0</td>
<td>2.97</td>
<td>5.94</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.0</td>
<td>3.51</td>
<td>4.91E-05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.1</td>
<td>5.28</td>
<td>2.97E-05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>0.0</td>
<td>1.91</td>
<td>2.91E-05</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G3 (Trigalactosylated)</td>
<td>0.2</td>
<td>0.0</td>
<td>2.71</td>
<td>3.80</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.0</td>
<td>3.54</td>
<td>7.07E-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>0.1</td>
<td>7.07</td>
<td>3.80E-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>0.0</td>
<td>1.65</td>
<td>3.80E-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>G4 (Tetragalactosylated)</td>
<td>0.0</td>
<td>0.0</td>
<td>3.04</td>
<td>3.04E-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.0</td>
<td>6.99</td>
<td>6.99E-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>0.1</td>
<td>6.12</td>
<td>6.12E-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>0.0</td>
<td>1.65</td>
<td>1.65E-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HM (High-mannose glycan)</td>
<td>0.0</td>
<td>0.0</td>
<td>8.51</td>
<td>2.38</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.0</td>
<td>6.99</td>
<td>6.99E-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.0</td>
<td>3.00</td>
<td>3.00E-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>0.0</td>
<td>1.68</td>
<td>1.68E-01</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>B (bisecting N-acetylglucosamine containing glycan)</td>
<td>-</td>
<td>-</td>
<td>7.37</td>
<td>3.44</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.0</td>
<td>0.0</td>
<td>7.85</td>
<td>7.85E-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.1</td>
<td>0.0</td>
<td>1.83</td>
<td>1.83E-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>0.2</td>
<td>0.0</td>
<td>8.20</td>
<td>8.20E-03</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Effect - beta coefficient estimated based on regression model, SE - standard error of estimated beta coefficient, p.val - p-value, q.val - adjusted p-value using a FDR approach. Each TRAIT represents a sum of chromatographic peaks corresponding to glycanas with similar structural features. LB - monoantennary and biantennary glycanas, HB - tri-antennary and tetra-antennary glycanas, S0 - glycanas with no sialic acid, S1 - glycanas with one sialic acid, S2 - glycanas with two sialic acids, S3 - glycanas with three sialic acids, S4 - glycanas with four sialic acids, G0 - glycanas with no galactose, G1 - glycanas with one galactose, G2 - glycanas with two galactoses, G3 - glycanas with three galactoses, G4 - glycanas with four galactoses, HM - high-mannose glycanas, B - glycanas that contain bisecting N-acetylglucosamine
Graphical Abstract

Highlights

- Relative occurrences of high-branched plasma N-glycans are increased in chronic low back pain
- Plasma protein N-glycosylation changes are consistent with chronic inflammation
- Relative occurrences of disialylated and trisialylated glycans change in chronic low back pain
- Specific glycan changes have a potential as biomarker for chronic low back pain
Chronic Low Back Pain

Graphics Abstract

N-acetylglucosamine
Fucose
Mannose
Galactose
N-acetylneuraminic acid

Plasma glycoproteins

N-glycans

High-branched Disialylated Trisialylated
Figure 1